The core idea is straightforward but powerful: instead of waiting for activity readouts that often ignore stereochemistry, the team uses biosensors that translate enantiomer preference into a measurable signal. When a microbial library of enzyme variants is tested, the biosensor response encodes which enantiomer the pathway favors, allowing researchers to distinguish “chemically active” from “stereochemically correct” candidates.

Technically, the approach couples genotype-to-phenotype evaluation with stereospecific readouts. Candidate variants are expressed in cells, fed substrates, and monitored through sensor outputs that reflect binding or recognition events tied to enantiomer formation. Because the signal is tied to chirality—not merely product quantity—the selection pressure becomes explicitly stereochemical.

This strategy addresses a longstanding bottleneck in biocatalyst engineering. Traditional assays can be slow, labor-intensive, or dependent on downstream chiral chromatography, which limits how many variants can be iterated. By contrast, biosensors enable higher-throughput screening and can be run in formats compatible with iterative cycles of mutation and selection.

The researchers also emphasize the importance of sensor calibration and dynamic range, since subtle shifts in enantiomeric excess must be captured reliably to guide evolution. In practice, sensor performance defines the sensitivity of selection, shaping which mutations survive to the next round.

Asymmetric biocatalysts are central to greener chemical manufacturing, particularly for pharmaceuticals and fine chemicals where chirality often determines therapeutic efficacy. Improved enzymes can replace harsher catalysts and reduce waste, making stereocontrolled synthesis more sustainable.

Overall, the study reframes enzyme evolution as an information problem: the “winning” variants are those that not only act, but act with the right handedness. With enantioselective biosensors turning stereochemistry into a real-time signal, the path to tailored catalysts may become faster, more automated, and more scalable.

In the coming years, expect biosensor-guided evolution to expand beyond chirality alone—potentially incorporating other molecular features such as substrate specificity, pathway flux, or toxicity. For now, this work highlights a compelling route to evolve asymmetric biocatalysts where selection is guided by the mirror-image outcome itself.

Subject of Research: Enantioselective biosensors for directed evolution of asymmetric biocatalysts.

Article Title: Using enantioselective biosensors to evolve asymmetric biocatalysts.

Article References: d’Oelsnitz, S., Kim, W., Zhao, N.N. et al. Using enantioselective biosensors to evolve asymmetric biocatalysts. Nat Chem Biol (2026). https://doi.org/10.1038/s41589-026-02275-1

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41589-026-02275-1

Enzymes, as biological catalysts, underpin countless biochemical reactions and are indispensable across industries ranging from food production to pharmaceuticals. However, naturally occurring enzymes often fall short of the robustness, specificity, and catalytic efficiency demanded by commercial processes. Traditional approaches to improve these biomolecules rely heavily on directed evolution, a strategy that mimics natural selection by generating vast libraries of enzyme variants through gene mutagenesis and then screening for desirable traits. Although powerful, the scale of mutant libraries—sometimes reaching up to 100 trillion variants—renders screening laborious and expensive.

Addressing these challenges head-on, the SMART system represents a paradigm shift in enzyme screening. Unlike conventional methods that struggle to correlate phenotypic function with genotype efficiently, SMART leverages the power of mRNA display technology. By chemically coupling an enzyme directly to its messenger RNA (mRNA) through a puromycin linker, SMART maintains the physical connection between a variant’s catalytic output and its corresponding genetic information. This unique molecular tether enables precise tracking of enzymes and their encoding sequences simultaneously, facilitating high-throughput functional assessments at an unprecedented single-molecule resolution.

A key innovation within SMART lies in its auxiliary detection unit, which amplifies the readout of enzymatic activity. The research team employed an engineered enzyme, ascorbate peroxidase 2 (APEX2), fused with the scCro DNA-binding domain and tethered to the system via ORC hairpin DNA structures. When the target enzyme catalyzes reactions producing hydrogen peroxide, APEX2 reacts by biotinylating nearby proteins. This biotin tag serves as a handle for magnetic bead-based isolation of active enzyme-mRNA complexes, enabling selective capture and enrichment for downstream analysis.

To evaluate SMART’s capabilities, scientists focused on a yeast-derived oxidase known as SpDAAO. Oxidases are particularly challenging due to the subtle and transient nature of their catalytic outputs. The choice of SpDAAO also aligns with growing interest in D-amino acids for pharmaceutical applications, offering a model system with both industrial and therapeutic relevance. By generating an extensive mutant library targeting the critical 232nd amino acid residue, the team employed iterative cycles of in vitro transcription, translation, enzymatic activity labeling, and next-generation sequencing to map functional landscapes rapidly.

Their experimental data demonstrated remarkable enrichment of active variants after just a single selection round, showcasing SMART’s sensitivity and selectivity. Significantly, the wild-type residue at position 232 was consistently prioritized in enriched pools, validating the platform’s accuracy. Subsequent statistical rigor revealed that minor variants initially indicated by raw sequencing data were likely experimental noise, underscoring the importance of comprehensive bioinformatic scrutiny alongside biochemical assays.

SMART’s integration of mRNA display techniques, advanced sequencing, and enzymatic biotinylation provides a robust framework that potentially transcends oxidase targets. By manipulating the auxiliary enzyme component to suit different enzymatic classes, this platform could broaden its scope to encompass hydrolases, lyases, and beyond. Additionally, its streamlined workflow reduces screening times from months or years to mere days or weeks, dramatically accelerating the pace of enzyme optimization.

The implications of this technology are profound. Industries dependent on enzyme catalysts may soon harness SMART to tailor biocatalysts with enhanced stability, substrate range, or reaction rates, enabling greener chemical processes and novel drug production routes. Moreover, the single-molecule resolution offers insights into enzyme heterogeneity and mechanistic nuances that bulk assays obscure, paving the way for fundamental advances in protein science.

Despite its transformative promise, the team acknowledges that rigorous experimental design and data analysis remain crucial to harness SMART’s full potential. Ensuring reproducibility and minimizing noise will be vital, especially as the platform is adapted to more complex enzymatic systems and real-world substrates. The researchers envision creating standardized protocols and computational tools to streamline SMART’s adoption across laboratories and industries worldwide.

Envisioning a future where enzyme engineering no longer wrestles with the constraints of scale and efficiency, the Nagoya team’s SMART technology stands as a beacon of innovation. Beyond expanding the enzyme repertoire available for biotechnology, this method embodies a new era where molecular precision and rapid iteration converge, unlocking biological functions with unprecedented agility.

The fusion of cutting-edge molecular biology techniques, protein engineering, and bioinformatics underscores the holistic approach required for next-generation biocatalyst development. As researchers continue to refine SMART and explore its myriad applications, the boundaries of what enzymes can achieve—in medicine, sustainability, and manufacturing—are poised to expand dramatically.

This pioneering work, published in ACS Synthetic Biology, not only showcases technological ingenuity but also exemplifies the collaborative spirit bridging academia and interdisciplinary research institutes. Supported by multiple grants and initiatives, the SMART platform exemplifies how sustained investment in scientific innovation translates into tools that could reshape biotechnology’s future landscape.

Subject of Research: Not applicable

Article Title: Harnessing the Power of SMART Single-Molecule Display for Enzyme Evolution: A Focus on Oxidase

News Publication Date: 23-Feb-2026

Web References:
10.1021/acssynbio.5c00968

Image Credits: Hideo Nakano and Jasmina Damnjanović

Keywords: enzyme engineering, directed evolution, mRNA display, single-molecule assay, oxidase, biocatalysis, protein evolution, SMART system, next-generation sequencing, puromycin linker, ascorbate peroxidase 2, biotinylation